



# CONCORD DRUGS LIMITED

CIN No. : L24230TG1995PLC020093

Regd. Office & Factory : Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R. Dist. - 501 511. (T.S) INDIA.

Admin Office : 3-11-451, L B Nagar, Hyderabad - 500074

E-mail : concorddrugsitd@gmail.com

Ph.No : +91 9052779505

Website : www.concorddrugs.in

To,

Date: 13.02.2024

**BSE Limited**  
**P.J. Towers, Dalal Street**  
**Mumbai- 400001**

Dear Sir/ Madam,

**Sub: Outcome of Board Meeting held on 13.02.2024**

**Ref: Our Company's letter dated 06.02.2024**

**Unit: Concord Drugs Limited (Scrip Code: 538965)**

With reference to the subject cited, this is to inform the exchange that the Board of Directors of **Concord Drugs Limited** at its meeting held on Tuesday, the 13<sup>th</sup> day of February, 2024 at the registered office of the company at 1:00 p.m., approved the following items of business:


1. Un-audited Financial Results (Standalone and Consolidated) for the Quarter ended 31<sup>st</sup> December, 2023. (**Enclosed as Annexure**).
2. Limited Review Report (Standalone and Consolidated) for the Quarter ended 31<sup>st</sup> December, 2023. (**Enclosed as Annexure**).
3. Appointment of M/s. Vivek Surana & Associates., practicing company secretaries, as Secretarial Auditor of the Company for the FY 2023-24. (**Brief Profile is annexed as Annexure - I**)
4. Appointment of M/s. Nazeerudeen & Co., Chartered Accountants, as Internal Auditor of the Company for the FY 2023-24. (**Brief Profile is annexed as Annexure - II**)

The meeting concluded at 5.50 p.m.

This is for the information and records of the Exchanges, please.

Thanking you.

**Yours sincerely,**  
**For Concord Drugs Limited**

  
**S. Nagi Reddy**  
**Chairman & Managing Director**  
**(DIN- 01764665)**

**Encl. as above**



**Annexure I**

**Brief Profile of M/s. Vivek Surana & Associates, Practicing Company Secretaries as Secretarial Auditor of the Company**

The details required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular CIR/CFD/CMD/4/2015 dated 9th September, 2015

Particulars	M/s. Vivek Surana & Associates
Reason for change viz. appointment, resignation, removal, death or otherwise	Appointment of M/s. Vivek Surana & Associates, Practicing Company Secretaries as Secretarial Auditor of the Company.
Date of appointment & Terms of appointment	Appointed on 13.02.2024 for the Financial Year 2023-24
Brief Profile	Vivek Surana & Associates, is a Practicing Company Secretaries firm based at Hyderabad providing secretarial, listing and other advisory services. The firm has existence of more than a decade in the above said services.
Disclosure of relationships between directors (in case of appointment of a director)	NA

**Annexure II**

**Brief Profile of M/s. Nazeerudeen & Co., as Internal Auditor of the Company**

The details required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular CIR/CFD/CMD/4/2015 dated 9th September, 2015

Sl.No	Particulars	Details
1.	reason for change viz. appointment, resignation, removal, death or otherwise	Appointment of M/s. Nazeerudeen & Co., Chartered Accountants as Internal Auditor of the Company
2.	date of appointment/cessation (as applicable) & term of appointment	Appointed on 13.02.2024 for the Financial Year 2023-24
3.	brief profile (in case of appointment);	Nazeerudeen & Co is a Chartered Accountants firm based at Hyderabad providing accounting, taxation, audit related services. Mr. Nazeerudeen is having rich experience of more than 10 years in above mentioned services.
4.	disclosure of relationships between directors (in case of appointment of a director).	Not Applicable

S. N. S. S.





# CONCORD DRUGS LIMITED

CIN No. : L24230TG1995PLC020093

Regd. Office &amp; Factory : Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R. Dist. - 501 511. (T.S) INDIA.

Admin Office : 3-11-451, L B Nagar, Hyderabad - 500074

E-mail : concorddrugsld@gmail.com

Ph.No : +91 9052779505

Website : www.concorddrugs.in

## STATEMENT OF UN AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DECEMBER 2023

[Rs. in Lakhs]

Particulars	Quarterly ended		Nine months ended			
	31-Dec-23 (un Audited)	30-Sep-23 (un Audited)	31-Dec-22 (un Audited)	31-Dec-23 (un Audited)	31-Dec-22 (Un Audited)	31-Mar-23 (Audited)
<b>I Revenue from Operations</b>						
a. Net sales from Operations	1,262.435	738.23	1,352.71	2,879.51	3,977.42	5,131.43
b. Other Operating Income	0.005	0.82	0.12	0.81	0.81	0.89
<b>II Other Income</b>						
<b>III Total Revenue (I+II)</b>	<b>1,262.440</b>	<b>739.05</b>	<b>1,352.83</b>	<b>2,880.32</b>	<b>3,978.23</b>	<b>5,132.31</b>
<b>IV Expenses</b>						
a. Cost of Material Consumed	1,043.646	473.67	1,002.88	2,091.51	2,977.84	4,035.53
b. Changes in inventories of finished goods, work-in-progress and stock-in-trade	1.205	-44.95	-32.00	-31.52	44.30	51.56
c. Employees Benefit Expenses	120.328	127.83	130.63	369.65	361.86	463.42
d. Finance Costs	43.176	39.03	44.92	121.25	120.79	162.45
e. Depreciation and Amortisation expense	38.489	38.41	37.97	114.81	129.53	160.25
f. Other expenses	41.109	28.81	106.83	100.92	233.09	146.56
<b>Total Expenses</b>	<b>1,297.953</b>	<b>662.81</b>	<b>1,291.23</b>	<b>2,766.60</b>	<b>3,867.41</b>	<b>5,019.76</b>
<b>Profit/ (Loss) before Exceptional item and tax (III-IV)</b>	<b>-25.513</b>	<b>76.24</b>	<b>61.60</b>	<b>113.72</b>	<b>110.82</b>	<b>112.56</b>
<b>V Exceptional Items</b>	-	-	-	-	-	-
<b>VI Profit/ (Loss) before tax (V-VI)</b>	<b>-25.513</b>	<b>76.24</b>	<b>61.60</b>	<b>113.72</b>	<b>110.82</b>	<b>112.56</b>
<b>VII Tax Expense:</b>						
a. Current tax	-1.566	23.61	16.17	36.38	28.54	23.34
b. Deferred tax charge/credit	-0.429	24.72	16.68	41.81	32.38	34.77
<b>IX Profit/ (Loss) for the period (VII-VIII)</b>	<b>-1.137</b>	<b>-1.11</b>	<b>-0.51</b>	<b>-5.43</b>	<b>-3.84</b>	<b>-13.43</b>
<b>X Other Comprehensive Income</b>	<b>-23.946</b>	<b>52.63</b>	<b>45.43</b>	<b>77.34</b>	<b>82.28</b>	<b>89.22</b>
Items that will not be reclassified to profit or loss	-	-	-	-	-	-
<b>Total Comprehensive Income for the period (comprising profit and other comprehensive income for the period) (IX+X)</b>	<b>-23.946</b>	<b>52.63</b>	<b>45.430</b>	<b>77.34</b>	<b>82.280</b>	<b>89.22</b>
<b>XI Paid up Capital</b>						
(Face value of the share- Rs. 10 each)	1,000.000	931.55	874.38	1,000.00	874.38	931.55
<b>Other Equity</b>						
<b>XII Earnings per share (of Rs. 10 each)</b>						
a. Basic (In Rs)	2,417.184	2,382.52	2,147.60	2,417.18	2,147.600	2,238.88
b. Diluted (In Rs)	-0.24	0.56	0.52	0.77	0.94	0.96
	-0.24	0.56	0.52	0.77	0.94	0.96

## Notes:

- The financial results of the company have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act, 2013, read with the relevant rules issued there under.
- The above standalone financial results as reviewed by the audit committee have been approved by Board of Directors at its meeting held on 13.02.2024
- Figures of the corresponding previous periods are regrouped and reclassified wherever considered necessary to correspond with current period's presentation.
- The results are also available on the website of the Company www.concorddrugs.in

Place: Hyderabad  
Date: 13.02.2024By Order of the Board  
For Concord Drugs Limited  
Managing Director  
DIN: 01764665



# CONCORD DRUGS LIMITED

CIN No. : L24230TG1995PLC020093

Regd. Office &amp; Factory : Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R. Dist. - 501 511. (T.S) INDIA.

Admin Office : 3-11-451, L B Nagar, Hyderabad - 500074

E-mail : concorddrugsltd@gmail.com

Ph.No : +91 9052779505

Website : www.concorddrugs.in


**STATEMENT OF UN AUDITED Consolidated FINANCIAL RESULTS FOR THE QUARTER ENDED 31st DECEMBER 2023**

(Rs. in Lakhs)

Particulars	Quarterly ended			Nine Months ended		
	31-Dec-23 (Un Audited)	30-Sep-23 (Un Audited)	31-Dec-22 (Un Audited)	31-Dec-23 (Un Audited)	31-Dec-22 (Un Audited)	31-Mar-23 (Audited)
<b>I Revenue from Operations</b>						
a. Net sales from Operations	1,278.37	751.67	1,352.71	2,928.21	3,977.42	5,208.06
b. Other Operating Income	0.00	0.81	0.12	0.81	0.81	0.89
<b>II Other Income</b>						
<b>III Total Revenue (I+II)</b>	<b>1,278.37</b>	<b>752.48</b>	<b>1,352.83</b>	<b>2,929.02</b>	<b>3,978.23</b>	<b>5,208.94</b>
<b>IV Expenses</b>						
a. Cost of Material Consumed	1,096.16	488.08	1,002.88	2,182.66	2,977.84	4,316.16
b. Changes in Inventories of finished goods, work-in-progress and stock-in-trade	-84.06	-78.94	-32.00	-182.53	44.30	-15.67
c. Employees Benefit Expenses	153.93	146.33	130.63	438.57	361.86	491.90
d. Finance Costs	49.67	42.65	44.92	136.38	120.79	170.62
e. Depreciation and Amortisation expense	38.93	38.83	37.97	116.10	129.53	162.56
f. Other expenses	49.43	35.73	106.83	120.21	233.09	158.49
<b>Total Expenses</b>	<b>1,304.06</b>	<b>672.68</b>	<b>1,291.23</b>	<b>2,811.39</b>	<b>3,867.41</b>	<b>5,084.05</b>
<b>Profit/ (Loss) before Exceptional item and tax (III-IV)</b>	<b>-25.69</b>	<b>79.80</b>	<b>61.60</b>	<b>117.63</b>	<b>110.82</b>	<b>124.89</b>
<b>V Exceptional Items</b>						
<b>VI Profit/ (Loss) before tax (V-VI)</b>	<b>-25.69</b>	<b>79.80</b>	<b>61.60</b>	<b>117.63</b>	<b>110.82</b>	<b>124.89</b>
<b>VII Tax Expense:</b>						
a. Current tax	-1.57	23.62	16.17	36.51	29.54	26.34
b. Deferred tax charge/credit	-0.43	24.72	16.68	41.94	32.38	37.87
<b>VIII Profit/ (Loss) for the period (VII-VIII)</b>	<b>-24.12</b>	<b>56.18</b>	<b>45.43</b>	<b>81.12</b>	<b>82.28</b>	<b>98.55</b>
<b>X Other Comprehensive Income</b>						
Items that will not be reclassified to profit or loss	-	-	-	-	-	-
<b>Total Comprehensive Income for the period (comprising profit and other comprehensive income for the period) (IX+X)</b>	<b>-24.12</b>	<b>56.18</b>	<b>45.43</b>	<b>81.12</b>	<b>82.28</b>	<b>98.55</b>
<b>XI Paid up Capital</b>						
(Face value of the share- Rs. 10 each)	1,000.00	931.55	874.38	1,000.00	874.38	931.55
<b>Other Equity</b>						
<b>XII Earnings per share (of Rs. 10 each)</b>	<b>2,417.05</b>	<b>2,382.52</b>	<b>2,147.60</b>	<b>2,417.05</b>	<b>2,147.60</b>	<b>2,238.88</b>
<b>XIII a. Basic (in Rs)</b>	<b>-0.24</b>	<b>0.60</b>	<b>0.52</b>	<b>0.81</b>	<b>0.94</b>	<b>1.06</b>
<b>b. Diluted (in Rs)</b>	<b>-0.24</b>	<b>0.60</b>	<b>0.52</b>	<b>0.81</b>	<b>0.94</b>	<b>1.06</b>

**Notes:**

- The financial results of the company have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act, 2013, read with the relevant rules issued there under.
- The above standalone financial results as reviewed by the audit committee have been approved by Board of Directors at its meeting held on 13th February, 2024.
- Figures of the corresponding previous periods are regrouped and reclassified wherever considered necessary to correspond with current period's presentation.
- On March 26, 2023 The company has Acquired 100% of equity Shares of Proton Remedies Private Limited for a total consideration of 1,41,50,000 (50,000 equity shares of Rs 283 each), further following the principles of Ind As 110 the results of the operations of Proton private limited have been consolidated into the operations of company from march 23, 2023 onwards.
- The results are also available on the website of the Company www.concorddrugs.in

Place: Hyderabad  
Date: 13th February, 2024By Order of the Board  
For Concord Drugs Limited  
  
Managing Director  
DIN: 01764665



# PUNDARIKASHYAM AND ASSOCIATES

## CHARTERED ACCOUNTANTS

# 1-8-435/436, 2nd Floor, Durga Towers, Beside Rasoolpura Metro Station, Begumpet,  
Hyderabad, Telangana - 500016. Cell : 9440464339, Ph : 040-35175033

E-mail : info@pkas.in / infoong@pkas.in

GSTIN : 36AAJFP6218J1ZY

- Branches : 1. Door No. 76-14-243/1A, Vasavi Kalyana Mandapam Road, Sivalayam Centre, Bhavani Puram, Vijayawada - 12.  
2. 7-310, Shop No. 204, Padma Towers, South Bypass Road, Ongole, 523001.  
3. Flat No. 202, 2nd Floor, Vijaya Ganapathi Nilayam, Ayyappa Nagar, Murali Nagar, Near Masjid Junction, Visakhapatnam, Andhra Pradesh - 530007.

### **Independent Auditor's Review Report on Standalone Unaudited Quarterly and Year to Date Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

#### **To the Board of Directors of Concord Drugs Limited,**

1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of Concord Drugs Limited ('the company') for the quarter ended 31 December 2023, and the year to date results for the period 1 April 2023 to 31 December 2023, being submitted by the Company pursuant to the requirements of the regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time.
2. The statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the act'), SEBI circular CIR/CFD/FAC/62/2016, dated 5 July 2016, (hereinafter referred to as 'the SEBI Circular'), and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we



would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act, the SEBI Circular, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Pundarikashyam and Associates**

Chartered Accountants

Firm Regn. No.011330S

*B. Surya Prakasa Rao*

B. Surya Prakasa Rao

Partner

Membership No.205125

UDIN: 24205125BKA DD X 2299



Place: Hyderabad

Date: 13.02.2024



# PUNDARIKASHYAM AND ASSOCIATES

CHARTERED ACCOUNTANTS

# 1-8-435/436, 2nd Floor, Durga Towers, Beside Rasoolpura Metro Station, Begumpet,  
Hyderabad, Telangana - 500016. Cell : 9440464339, Ph : 040-35175033

E-mail : info@pkas.in / infoong@pkas.in

GSTIN : 36AAJFP6218J1ZY

- Branches : 1. Door No. 76-14-243/1A, Vasavi Kalyana Mandapam Road, Sivalayam Centre, Bhavani Puram, Vijayawada - 12.  
2. 7-310, Shop No. 204, Padma Towers, South Bypass Road, Ongole, 523001.  
3. Flat No. 202, 2nd Floor, Vijaya Ganapathi Nilayam, Ayyappa Nagar, Murali Nagar, Near Masjid Junction, Visakhapatnam, Andhra Pradesh - 530007.

## Independent Auditor's Review Report on Consolidated Unaudited Quarterly and Year to Date Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Concord Drugs Limited,

1. We have reviewed the accompanying statement of Consolidated unaudited financial results ('the Statement') of Concord Drugs Limited ('the group company') for the quarter ended 31 December 2023, and the year to date results for the period 1 April 2023 to 31 December 2023, being submitted by the Company pursuant to the requirements of the regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time.
2. The statement, which is the responsibility of the Group Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the act'), SEBI circular CIR/CFD/FAC/62/2016, dated 5 July 2016, (hereinafter referred to as 'the SEBI Circular'), and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we



would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act, the SEBI Circular, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Pundarikashyam and Associates**

Chartered Accountants

Firm Regn. No.011330S

B. *Surya Prakasa Rao*  
B. Surya Prakasa Rao

Partner

Membership No.205125

UDIN: 24205125BKA DD 73212



Place: Hyderabad

Date: 13.02.2024.